Eli Lilly Q2 2026: Revenue Hits $23B, Guidance Raised

Eli Lilly's second-quarter earnings demolish expectations by $2.3 billion, fueled by record Mounjaro and Zepbound demand, sending LLY shares surging more than 6.5%.

Q2 revenue reached $23.0 billion, a 48% year-over-year increase, beating consensus estimates of $20.6 billion by $2.3 billion.
Non-GAAP EPS of $8.38 topped the $6.01 analyst estimate by 39%, the largest quarterly earnings surprise in recent company history.
Full-year 2026 revenue guidance was raised to $85–$87 billion, up from the prior $82–$85 billion range.

Lead

Indianapolis, August 5, 2026 — Eli Lilly ($LLY) delivered its most expansive quarterly performance on record, reporting second-quarter 2026 revenue of $23.0 billion — a 48% jump from the prior-year period — and raising its full-year revenue outlook for the third consecutive quarter. Shares of the Indianapolis-based drugmaker climbed more than 6.5% on the session, adding roughly $50 billion to the company's market capitalization in a single trading day, as Wall Street digested a result that cleared already elevated expectations by a wide margin.

What Happened

The numbers inside the eli lilly building were unambiguous. Combined sales of Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) reached $14.9 billion in the quarter, accounting for the vast majority of total company revenue and cementing Lilly's position as the dominant force in the global glucagon-like peptide-1 (GLP-1) drug market.

Mounjaro generated $9.94 billion in quarterly revenue — $4.8 billion in the U.S. and $5.2 billion internationally — a 91% year-over-year advance driven by accelerating adoption across major markets in Europe and Asia. Zepbound contributed $4.9 billion in U.S. sales, a 44% increase year-over-year, despite pricing headwinds following recent list price reductions aimed at expanding access. Demand for the zepbound pen — the injectable auto-injector format — has continued to absorb incremental manufacturing capacity as Lilly has expanded production at facilities in Indiana, North Carolina, and Germany.

Non-GAAP earnings per share reached $8.38, exceeding the Street's $6.01 consensus by $2.37, a 39.4% positive surprise. GAAP results were modestly lower due to $3.03 per share in acquired in-process research and development charges tied to pipeline acquisitions.

Market Reaction

LLY opened sharply higher and sustained gains through the session, closing up approximately 6.5% on heavy volume. The move reflected not only the magnitude of the revenue and earnings beat but also the credibility of management's upward revision to full-year guidance. Across the broader pharmaceutical and biotechnology sectors, Lilly's results reignited investor appetite for obesity drug exposure after competitor Novo Nordisk earlier in the day reported disappointing results, citing supply constraints and weaker-than-expected prescription trends for Wegovy and Ozempic.

Strategic Context

Chief Executive David Ricks characterized the quarter as evidence of durable structural demand, noting in prepared remarks that the company has reached a position of strength it has rarely occupied historically. Lilly's newly launched oral GLP-1 therapy, Foundayo, which entered the U.S. market in April 2026, adds a third commercial pillar to the company's metabolic disease franchise and broadens the addressable patient population beyond those who prefer or tolerate injectable formats such as the zepbound pen.

The divergence between Lilly and Novo Nordisk has widened materially. While Novo reported growth deceleration across both Wegovy and Ozempic and cut its full-year operating profit forecast, Lilly raised its FY26 revenue guidance to $85–$87 billion from the prior $82–$85 billion range, a $3 billion midpoint increase. On EPS, guidance was refined to $35.50–$36.50, incorporating the acquired IPR&D charges but still representing a meaningful improvement in underlying profitability expectations.

Pipeline and Manufacturing

Retatrutide, Lilly's next-generation triple agonist in late-stage development, completed its Phase 3 clinical data package during the quarter, with positive results across obesity, obstructive sleep apnea, and knee osteoarthritis indications. The company expects to submit for global regulatory approvals in the near term, which would further extend its lead in metabolic and cardiometabolic medicine. Unlike Novo Nordisk, Lilly reported no significant manufacturing constraints during the quarter, a function of multi-year capital investment in production capacity that management began accelerating in 2023.

Outlook

Lilly's revised FY26 guidance of $85–$87 billion in revenue represents a structural step-up from the trajectory that opened the year. Continued volume growth in Mounjaro and Zepbound, the commercial ramp of Foundayo, and the prospective filing of retatrutide position the company to sustain above-market growth well into 2027. The contrast with Novo Nordisk — which now faces a declining full-year profit outlook — underscores how decisively the competitive balance in the GLP-1 market has shifted. With manufacturing capacity no longer the binding constraint it was two years ago and a deep late-stage pipeline, Eli Lilly enters the second half of 2026 as the uncontested leader in the most commercially significant therapeutic category in modern pharmaceutical history.

Impact: MAJOR